Drug Profile
Adeno-interleukin-3 gene therapy - Crucell
Alternative Names: Interleukin-3 gene therapy - IntroGeneLatest Information Update: 26 Jan 2005
Price :
$50
*
At a glance
- Originator Crucell
- Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
- Mechanism of Action Immunostimulants; Interleukin 3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sarcoma
Most Recent Events
- 25 Jan 2005 Discontinued - Preclinical for Sarcoma in Netherlands (IV)
- 25 Jun 1998 Preclinical development for Sarcoma in Netherlands (IV)